You are here Home Resources and guidance Publications Meeting statements ACV meeting statement, meeting 57, 30 September 2026 Advisory Committee on Vaccines Published 29 October 2026 Listen Print Share LinkedIn (Twitter) Facebook Email Loading... Section A: Premarket registration applicationsAt this meeting the committee provided advice on one application under evaluation by the TGA.Active ingredient (TRADENAME)SponsorTherapeutic areaApplication designationsApplication for a 'new indication', or additional therapeutic use, for an already approved Vaccine (Application Type C)Recombinant respiratory syncytial virus pre-fusion F protein(AREXVY)GlaxoSmithKline Australia Pty LtdLower respiratory tract disease The date of commencement of the evaluation of the application is available at Prescription medicines: Applications under evaluation.Further details of the ACV discussion and advice associated with items may be released within the Australian Public Assessment Reports (AusPARs).Section B: Post-market itemsThe ACV was not asked to provide advice on a post-market or safety issue.Further informationFor further information on the Advisory Committee on Vaccines, please visit: Advisory Committee on Vaccines (ACV), or contact the ACV Secretary by email: ACV@health.gov.au. Topics Safety monitoring and information Committees and advisory bodies Outcome of Advisory Committee on Vaccines (ACV)
